AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04662125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine, paracetamol tablet
Description: oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
Study NCT04662125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone
Description: patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
Study NCT04662125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral pregabalin
Description: patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
Study NCT02657291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic
Study NCT02657291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic
Study NCT02657291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound guided block
Study NCT02657291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided block
Study NCT00958750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minoxidil
Description: the investigators compared two different formulations and concentrations of minoxidil in this study
Study NCT02733471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT02733471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03051217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W
Study NCT03051217 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W
Study NCT03051217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use
Study NCT01024062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
Study NCT00610077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
Study NCT00610077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
Study NCT03135262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams \[mg\], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
Study NCT03135262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
Study NCT03135262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
Study NCT03135262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.
Study NCT03828786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratching
Description: Endometrial Biopsy by aspiration with a pipelle
Study NCT03777423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK framework partial dentures
Description: Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
Study NCT03777423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobalt- chromium framework partial dentures
Description: It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
Study NCT03674567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX475
Description: tablet
Study NCT00641706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT03533764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASMA
Description: ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
Study NCT02549937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: orally once daily (QD) in patients with advanced solid tumor.
Study NCT01421004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study NCT00662012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Stibogluconate (SSG)
Description: 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
Study NCT03955744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D translabial ultrasound
Description: All patients will undergo 3D translabial ultrasound with vaginal manometry
Study NCT03992001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood component A
Description: PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
Study NCT03992001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood component B
Description: PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
Study NCT03334903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
Study NCT02091934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided PRK
Description: Wavefront-guided PRK
Study NCT02091934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-optimized PRK
Description: Wavefront-optimized PRK
Study NCT02144012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
Study NCT02144012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
Study NCT02144012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was administered IV at either 75 milligrams/square meter (mg/m\^2) or 100 mg/m\^2 Q3W.
Study NCT01734863 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Study NCT02080949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4fx x 5Gy
Description: It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
Study NCT03910374 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dural closure
Description: Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
Study NCT03910374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural closure
Description: Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
Study NCT02612727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtered-sunlight phototherapy
Description: Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
Study NCT02612727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive phototherapy
Description: Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
Study NCT00394147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
Study NCT00394147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
Study NCT03206528 — intervention group
Intervention type: DEVICE
Intervention: Vital Signs Monitoring System
Description: The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
Study NCT02481232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: freeze-dried group ACYW135 MCV
Description: Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
Study NCT02088281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo naturalis extract in oil ointment
Description: Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
Study NCT03991572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repeated transcranial magnetic stimulation with real coil
Description: repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
Study NCT03991572 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repeated transcranial magnetic stimulation with sham coil
Description: repeated transcranial magnetic stimulation with sham coil is a placebo
Study NCT00176228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg.
Study NCT03778762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind tracheal intubation through AirQ
Description: underwent blind intubation with correction manoeuvres
Study NCT03778762 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fiberscopic tracheal intubation through AirQ
Description: : underwent fibreoptic guided intubation
Study NCT01446289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine
Description: Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
Study NCT01446289 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women who received one injection of saline solution administered intramuscularly.
Study NCT04534959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)
Description: Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 >96% or PaO2 >100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
Study NCT01209260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency energy needle
Description: Radiofrequency energy needle for transseptal access
Study NCT01209260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Needle
Description: Mechanical needle for transseptal access
Study NCT03310775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-assisted social skills training program for young adult with ASD
Description: The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
Study NCT05015465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior Segment OCT
Description: AS-OCT for juvenile SLE patients and compare them with normal subjects
Study NCT03466008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-Body Cryotherapy
Description: 10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
Study NCT01031355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)
Description: Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
Study NCT01031355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate (EV) (BAY86-4980)
Description: Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
Study NCT01031355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levomefolate Calcium (BAY86-7660)
Description: Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
Study NCT03119584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linaclotide or placebo
Study NCT00803725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine without fentanyl
Description: 45 mg 1.5% mepivacaine injection for spinal anesthesia
Study NCT00803725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine with Fentanyl
Description: 10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
Study NCT01063452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Truvalve
Description: Atkinson Product Design urinary slide valve
Study NCT00641706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patient undergoes surgery
Study NCT00641706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01063452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (catheter drainage bag)
Description: urinary catheter drainage bag
Study NCT03570021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection
Description: total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association \[American Thyroid Association Surgery Working Group, Thyroid 2009\]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery \[French Society of Otolaryngology Head and Neck Sugery\].~- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection \[Hartl DM, Ann Surg 2012\], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons \[Hartl DM, World J Surg 2012\].
Study NCT03570021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total thyroidectomy alone without neck dissection
Description: This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
Study NCT02435784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Two-Way Communication Checklist
Description: The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
Study NCT02435784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Patients will attend a psychiatric consultation as usual.
Study NCT03230357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC guided by EDUG
Description: ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
Study NCT00251017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Two hour creatinine clearance before and after vancomycin
Study NCT00251017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DNA are extracted from the whole blood of subjects
Study NCT04520308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Only Product
Description: SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
Study NCT00087386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00087386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02619058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKT cells
Description: autologous natural killer T cell
Study NCT05475444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels
Description: antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
Study NCT05475444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin paste and solution
Description: Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection